Coverage
Filings
Orion's collaboration partner Bayer announced U.S. FDA approval for darolutamide, an androgen receptor inhibitor (ARi), for metastatic hormone-sensitive prostate cancer (mHSPC).
| 7 Aug 2009 |
| Orion comments on ANDA filed by Sandoz Inc. for a generic version of Orion's proprietary drug Precedex® (dexmedetomidine hydrochloride 100 mcg base/ml ) in the United States | 31 Jul 2009 |
| Orion invites analysts and media to Q2 news conference on Friday 7 August 2009 | 10 Jun 2009 |
| Orion reacquires rights for i.v. levosimendan (Simdax®) | 6 May 2009 |
| Orion and Wockhardt settle patent dispute | 29 Apr 2009 |